Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Initiation and progression of liver fibrosis requires proliferation and activation of resting hepatic stellate cells (HSCs). Cyclin E1 (CcnE1) is the regulatory subunit of the cyclin‐dependent kinase 2 (Cdk2) and controls cell cycle re‐entry. We have recently shown that genetic inactivation of CcnE1 prevents activation, proliferation, and survival of HSCs and protects from liver fibrogenesis. The aim of the present study was to translate these findings into preclinical applications using an RNA interference (RNAi)‐based approach. CcnE1‐siRNA (small interfering RNA) efficiently inhibited CcnE1 gene expression in murine and human HSC cell lines and in primary HSCs, resulting in diminished proliferation and increased cell death. In C57BL/6 wild‐type (WT) mice, delivery of stabilized siRNA using a liposome‐based carrier targeted approximately 95% of HSCs, 70% of hepatocytes, and 40% of CD45+ cells after single injection. Acute CCl 4‐mediated liver injury in WT mice induced endogenous CcnE1 expression and proliferation of surviving hepatocytes and nonparenchymal cells, including CD45+ leukocytes. Pretreatment with CcnE1‐siRNA reverted CcnE1 induction to baseline levels of healthy mice, which was associated with reduced liver injury, diminished proliferation of hepatocytes and leukocytes, and attenuated overall inflammatory response. For induction of liver fibrosis, WT mice were challenged with CCl 4 for 4‐6 weeks. Co‐treatment with CcnE1‐siRNA once a week was sufficient to continuously block CcnE1 expression and cell‐cycle activity of hepatocytes and nonparenchymal cells, resulting in significantly ameliorated liver fibrosis and inflammation. Importantly, CcnE1‐siRNA also prevented progression of liver fibrosis if applied after onset of chronic liver injury. Conclusion: Therapeutic targeting of CcnE1 in vivo using RNAi is feasible and has high antifibrotic activity. (H epatology 2017;66:1242‐1257).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061 · cited 1×
“The role of proliferating macrophages during liver fibrogenesis is controversially discussed,((21,22)) and our data supports a function of CcnE1 for proliferation of leukocytes.”
BackgroundSelf-citationHypertrophy and Unconventional Cell Division of Hepatocytes Underlie Liver Regeneration
Miyaoka, Y., Ebato, K., Kato, H., Arakawa, S., Shimizu, S., & Miyajima, A. (2012) · Current Biology · doi:10.1016/j.cub.2012.05.016 · Cited by 461 · cited 1×
“Liver regeneration and wound healing can occur without cell division by cellular hypertrophy.((17)) We thus determined the amount and size of hepatocytes as described recently.”
BackgroundBeddowes, E. J., Faux, S. P., & Chipman, J. K. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00058-1 · Cited by 113 · cited 1×
“This could prevent cell death attributed to replication of damaged DNA by several mechanisms.((11,23,24)) This idea is further supported by our genetic studies using hepatocyte-specific CcnE1 knockout mice in the CCl4 model.”
Result
Cited by
Targeting CDK2 in cancer: challenges and opportunities for therapy
Tadesse, S., Anshabo, A. T., Portman, N., Lim, E., Tilley, W., Caldon, C. E., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.001 · Cited by 333
Wan, T., Zhong, J., Pan, Q., Zhou, T., Ping, Y., & Liu, X. (2022) · Science Advances · doi:10.1126/sciadv.abp9435 · Cited by 299
Macrophage-specific FGF12 promotes liver fibrosis progression in mice
Li, S., Zhou, B., Xue, M., Zhu, J., Tong, G., Fan, J., Zhu, K., Hu, Z., Chen, R., Dong, Y., et al. (2023) · Hepatology · doi:10.1002/hep.32640 · Cited by 62
“For in vitro studies, macrophages are classified as “classically activated” M1 macrophages and “alternatively activated” M2 macrophages.[20,34] M1 macrophages highly express iNOS and secrete inflammatory factors to participate in inflammation, while M2 macrophages are identified as proreparative and secrete profibroti…”
BackgroundMethodChen, L., Gu, T., Li, B., Li, F., Ma, Z., Zhang, Q., Cai, X., & Lu, L. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.06.011 · Cited by 60
Zhu, X., Ye, S., Yu, D., Zhang, Y., Li, J., Zhang, M., Leng, Y., Yang, T., Luo, J., Chen, X., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15490 · Cited by 34
“A mouse model of liver fibrosis was established by i.p. injection of CCl4 (10% solution in olive oil) for 4 weeks (0.25-ml kg 1, three times a week; Bangen et al., 2017).”
MethodInfluential
Metadata
- Authors
- Bangen, J., Hammerich, L., Sonntag, R., Baues, M., Haas, U., Lambertz, D., Longerich, T., Lammers, T., Tacke, F., Trautwein, C., & Liedtke, C.
- Venue
- Hepatology
- Published
- 2017-08-26
- Volume
- 66
- Issue
- 4
- Pages
- 1242-1257
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2616475253
- Cited by
- 59
- References
- 4
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice. https://app.cochat.ai/papers/10.1002/hep.29275
- The paper
- Bangen, J., Hammerich, L., Sonntag, R., Baues, M., Haas, U., Lambertz, D., Longerich, T., Lammers, T., Tacke, F., Trautwein, C., & Liedtke, C. (2017). Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice. Hepatology. https://doi.org/10.1002/hep.29275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.